FDA Officially Approves Pfizer's Oral Anti-COVID-19 Drug Paxlovid for Adults with Mild to Moderate COVID-19 on May 25
FDA Grants Full Approval to Pfizer's Paxlovid for Treatment of Mild-to-Moderate COVID-19 in Adults
May 25, 2023 22:53
CST Updated
22:53
Pfizer
Pharmaceutical R&D Developer
FDA
U.S. Food and Drug Administration